Catalyst Biosciences, Inc. has completed the merger with Targacept, Inc. The combined company has approximately $39 million in cash to advance its R&D efforts, including the clinical development of CB 813d, Catalyst’s next-gen, long-acting coagulation Factor VIIa. CB 813d has demonstrated initial safety and pharmacologic activity to support Phase II trials in 2016 for the potential treatment of bleeding in hemophilia patients with inhibitors.   In connection with the merger, Targacep...